RxDoctor Payments Data

Elmer Smith, MD

Internal Medicine · Bedford, TXNPI 1699793992

Payments from drug & device makers

$15,915in general payments, 2019–2025

Across 767 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$845
  • AbbVie$815
  • Bayer$808
  • plus $10K from 53 others

What the payments were for

  • Speaking & faculty fees$480%
  • Food & beverage$15,49997%
  • Education$3182%
  • Other$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,915 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,049
Medicare patients
108
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$114,459
FarxigaDapagliflozin Propanediol82$72,233
MounjaroTirzepatide61$70,033
EliquisApixaban70$51,256
TrulicityDulaglutide47$49,325
JardianceEmpagliflozin32$39,476
EntrestoSacubitril/Valsartan43$38,230
VraylarCariprazine Hcl16$36,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,377
GemtesaVibegron62$20,740
KerendiaFinerenone11$11,968
LinzessLinaclotide12$7,600
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,752
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$4,201
Tresiba Flextouch U-100Insulin Degludec21$3,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$699$119,358108 claims
Novo NordiskOzempic$1,295$114,45984 claims
AstraZenecaFarxiga$1,273$72,23382 claims
PfizerEliquis$622$51,25670 claims
AbbVieVraylar, Linzess$815$44,16528 claims
Boehringer IngelheimJardiance$665$39,47632 claims
NovartisEntresto$359$38,23043 claims
GSKTrelegy Ellipta$600$21,37725 claims
Sumitomo Pharma America, Inc.Gemtesa$167$20,74062 claims
BayerKerendia$808$11,96811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →